• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Nosocomial Infections - Pipeline Review, H2 2012 Product Image

Nosocomial Infections - Pipeline Review, H2 2012

  • ID: 2245100
  • September 2012
  • 94 pages
  • Global Markets Direct

Nosocomial Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Nosocomial Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Nosocomial Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Nosocomial Infections. Nosocomial Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Nosocomial Infections.
- A review of the Nosocomial Infections products under development by companies READ MORE >

Note: Product cover images may vary from those shown

2
List of Tables 5
List of Figures 6
Introduction 7
REPORT COVERAGE 7
Nosocomial Infections Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Nosocomial Infections 9
Nosocomial Infections Therapeutics under Development by Companies 11
Nosocomial Infections Therapeutics under Investigation by Universities/Institutes 13
Late Stage Products 14
Comparative Analysis 14
Mid Clinical Stage Products 15
Comparative Analysis 15
Early Clinical Stage Products 16
Comparative Analysis 16
Discovery and Pre-Clinical Stage Products 17
Comparative Analysis 17
Nosocomial Infections Therapeutics – Products under Development by Companies 18
Nosocomial Infections Therapeutics – Products under Investigation by Universities/Institutes 19
Companies Involved in Nosocomial Infections Therapeutics Development 20
Shionogi & Co., Ltd. 20
AstraZeneca PLC 21
Rib-X Pharmaceuticals, Inc. 22
Cubist Pharmaceuticals, Inc. 23
Paratek Pharmaceuticals, Inc. 24
Intercell AG 25
Immupharma Plc 26
Priaxon AG 27
Atox Bio Inc. 28
Integrated BioTherapeutics, Inc. 29
Tetraphase Pharmaceuticals Inc. 30
Cantab Biopharmaceuticals Limited 31
Agennix AG 32
Nosocomial Infections – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
omadacycline - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
delafloxacin - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
talactoferrin alfa - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
NVB-333 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
IC-43 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
CXA201 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
CXA201 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
colistimethate sodium - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
aspirin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
aspirin - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
aspirin - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
AB-103 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
doripenem - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MAR Program - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
TP-434 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
IPP-203101 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CAZ104 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
Antiinfectives PXO Program - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
S. aureus Program - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
CXA-201 + Metronidazole - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CAZ104 + Metronidazole - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Nosocomial Infections Therapeutics – Drug Profile Updates 73
Nosocomial Infections Therapeutics - Dormant Products 85
Nosocomial Infections – Product Development Milestones 86
Featured News & Press Releases 86
Dec 13, 2011: Cubist Announces First Patient Dosed In Pivotal Global Phase III Trial Of CXA-201 For Complicated Intra-Abdominal Infections 86
Oct 14, 2011: Nationwide Children’s Hospital Clinical Trial To Use Drug To Boost Immune System Function In Critically Injured Children, May Prevent Infection 86
Oct 25, 2010: Intercell Announces Positive Results From Phase II Pseudomonas Aeruginosa Investigational Vaccine Study For Certain Hospital-Acquired Infections 87
Mar 18, 2010: Achillion Announces Award Of NIH Grant To Study Unique Antibacterial Compound Series 88
Jan 28, 2010: Theravance Receives Response Letter From FDA For Telavancin NDA For The Treatment Of Nosocomial Pneumonia 89
Dec 14, 2009: Cubist Pharmaceuticals To Acquire Calixa Therapeutics 90
Nov 30, 2009: Theravance Announces The Completion Of Validation Phase Of Telavancin MAA By The EMEA 91
Jul 03, 2009: Palumed Received A Support Of Oséo-France For Its Antibiotic Program 91
Dec 29, 2008: Intercell Starts Phase II Clinical Trial For Pseudomonas Aeruginosa Vaccine, IC43 91
Oct 07, 2008: Novacta Therapeutics Achieves First Milestone From The Wellcome Trust's Strategic Translational Award For NVB302, A New Treatment For C. difficile Infection 92
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94

List of Tables
Number of Products Under Development for Nosocomial Infections, H2 2012 9
Products under Development for Nosocomial Infections – Comparative Analysis, H2 2012 10
Number of Products under Development by Companies, H2 2012 12
Number of Products under Investigation by Universities/Institutes, H2 2012 13
Comparative Analysis by Late Stage Development, H2 2012 14
Comparative Analysis by Mid Clinical Stage Development, H2 2012 15
Comparative Analysis by Early Clinical Stage Development, H2 2012 16
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 17
Products under Development by Companies, H2 2012 18
Products under Investigation by Universities/Institutes, H2 2012 19
Shionogi & Co., Ltd., H2 2012 20
AstraZeneca PLC, H2 2012 21
Rib-X Pharmaceuticals, Inc., H2 2012 22
Cubist Pharmaceuticals, Inc., H2 2012 23
Paratek Pharmaceuticals, Inc., H2 2012 24
Intercell AG, H2 2012 25
Immupharma Plc, H2 2012 26
Priaxon AG, H2 2012 27
Atox Bio Inc., H2 2012 28
Integrated BioTherapeutics, Inc., H2 2012 29
Tetraphase Pharmaceuticals Inc., H2 2012 30
Cantab Biopharmaceuticals Limited, H2 2012 31
Agennix AG, H2 2012 32
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Stage and Molecule Type, H2 2012 38
Nosocomial Infections Therapeutics – Drug Profile Updates 73
Nosocomial Infections Therapeutics – Dormant Products 85

List of Figures
Number of Products under Development for Nosocomial Infections, H2 2012 9
Products under Development for Nosocomial Infections – Comparative Analysis, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 13
Late Stage Products, H2 2012 14
Mid Clinical Stage Products, H2 2012 15
Early Clinical Stage Products, H2 2012 16
Discovery and Pre-Clinical Stage Products, H2 2012 17
Assessment by Monotherapy Products, H2 2012 33
Assessment by Combination Products, H2 2012 34
Assessment by Route of Administration, H2 2012 35
Assessment by Stage and Route of Administration, H2 2012 36
Assessment by Molecule Type, H2 2012 37
Assessment by Stage and Molecule Type, H2 2012 38

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos